Anil Koul

rdf:langString Anil Koul

rdf:langString Anil Koul

rdf:langString Anil Koul

rdf:langString India

rdf:langString Institute of Microbial Technology, Chandigarh 160036, India. LSHTM, London, UK.

rdf:langString Max-Planck Institute for Biochemistry , Munich Germany & CSIR-IGIB Delhi and Delhi University, India

rdf:langString American Chemical Society - Heroes of Chemistry Award ; Sun Pharma Research Award ; Johnson Medal ; Swiss-TB prize

rdf:langString Anil Koul (born 1 June 1972) is a scientist and former Director of the CSIR-Institute of Microbial Technology (IMTECH), a premier biomedical and biotechnology research institution under Council of Scientific and Industrial Research (CSIR) under Ministry of Science and Technology, Govt. of India. Anil is currently a member of scientific advisory board of CSIR, a high powered committee for scientific management of CSIR organization, chaired by principal scientific adviser to the Prime Minister, Prof. Vijay Raghavan. Anil has more than 18 years of pharmaceutical R&D expertise and currently is vice president and Head of Global Public Health discovery at Johnson & Johnson (J&J). He is member of Board of Directors of Janssen Pharmaceutica NV, the European subsidiary of J&J. Additionally, Anil was recently appointed as Professor of Translational Discovery at London School of Hygiene and Tropical Medicine (LSHTM), where he will set up a laboratory of Translational drug discovery. Anil's major scientific career achievement is his key role in discovery and development of new tuberculosis drug Bedaquiline - the first drug to be approved in the last 45 years for treatment of drug-resistant tuberculosis.